Mexico stands at a critical juncture in its public health trajectory as cancer and cardiovascular disease continue to represent two of the leading causes of mortality and morbidity in the country—conditions that strain health systems, diminish quality of life, and carry profound economic consequences for families and communities across the nation. As Mexico advances its 2026 public health agenda, the choices made today in prevention, diagnosis, treatment, and health system design will determine outcomes for millions of people in the years ahead.
The burden of cancer and cardiovascular disease in Mexico is significant and growing. Despite advances in clinical knowledge and the availability of innovative therapies globally, access to timely diagnosis and effective treatment remains uneven across the country’s health institutions and regions. Gaps in early detection, limitations in healthcare infrastructure, and regulatory and financing challenges continue to delay patient access to care—and to the innovations that could meaningfully improve survival rates and quality of life. At the same time, Mexico’s health system is undergoing important institutional changes, creating both opportunities and risks for the direction of public policy in these critical areas.
The 2026 outlook for Mexico’s health agenda also unfolds within a broader regional context. The USMCA framework offers underexplored opportunities to advance healthcare innovation, facilitate access to new therapies, and align regulatory approaches across North America in ways that could benefit Mexican patients and strengthen the country’s health system. Regulatory agility, cross-border collaboration, and investment in health innovation ecosystems are increasingly central to how countries compete in delivering quality care to their populations.
What progress has Mexico made in strengthening prevention, diagnosis, and treatment of cancer and cardiovascular disease, and where do the most urgent gaps remain? How can public policy, clinical practice, and institutional coordination be improved to expand access to effective, evidence-based care? What role can regulatory reform, the USMCA, and international collaboration play in accelerating healthcare innovation and improving outcomes for Mexican patients?
Join the Mexico Program at the Dialogue on July 16th, 2026 from 10:00AM – 11:30AM ET for a timely and forward-looking conversation on Mexico’s evolving public health agenda, with a focus on cancer and cardiovascular health—assessing progress, identifying priority areas, and exploring the policy and institutional pathways needed to promote the well-being of the Mexican population.
OPENING REMARKS
MARÍA CALDERÓN
Senior Program Associate, Mexico Program, Inter-American Dialogue
MODERATOR
SANTIAGO MARCH
New technologies Director, Mexican Health Foundation (FUNSALUD)
SPEAKERS
ALFONSO DUEÑAS
Former Senior Researcher, National Cancer Institute of Mexico (INCan) and the National Autonomous University of Mexico (UNAM)
ANDREA GALLARDO
Coordinator of the Cardio-Oncology Chapter, Mexican Society of Cardiology
